Peripheral mechanical thrombectomy — the catheter-based clot removal for acute limb ischemia, DVT, and PE representing the critically urgent intervention for acute thrombotic events — creates an important and growing peripheral intervention market, with the Peripheral Intervention Market reflecting acute thrombectomy as a clinically urgent and commercially growing segment.

Acute limb ischemia intervention — the pharmacomechanical thrombolysis and mechanical thrombectomy for acute lower extremity arterial occlusion representing the vascular emergency intervention. The Penumbra Indigo aspiration system, Boston Scientific Trellis pharmacomechanical system, and AngioJet (Boston Scientific) catheter-directed thrombolysis platforms creating the acute limb ischemia treatment market.

Inari Medical disruption across venous thrombectomy — the ClotTriever system for DVT removal and FlowTriever for PE representing the company's comprehensive venous thrombectomy commercial strategy. Inari Medical's rapid commercial growth (from founding 2016 to approximately five hundred million dollar revenue) demonstrating the commercial opportunity in a previously underserved acute venous thrombosis mechanical treatment market.

AngioJet rheolytic thrombectomy — the established peripheral and coronary thrombectomy system using high-pressure saline jets to disrupt and aspirate thrombus — representing the long-established commercial thrombectomy platform. AngioJet's peripheral arterial application maintaining clinical use despite the growth of newer alternatives for venous applications.

Do you think Inari Medical's commercial success in venous thrombectomy will attract competitive entries from larger vascular device companies, or has Inari established sufficient clinical validation and operator loyalty to maintain market leadership?

FAQ

What is acute limb ischemia and how is it treated endovascularly? Acute limb ischemia (ALI): sudden reduction in limb perfusion; classification: Rutherford I (viable), IIa (marginally threatened), IIb (immediately threatened), III (irreversible); causes: embolism, thrombosis, graft occlusion, popliteal aneurysm thrombosis; endovascular treatment: catheter-directed thrombolysis (CDT) — alteplase infusion via catheter into thrombus; pharmacomechanical thrombectomy — Trellis (isolated segmental thrombolysis); aspiration thrombectomy — Indigo; AngioJet rheolytic; STILE and TOPAS trials: CDT versus surgery — CDT superior for subacute ischemia; surgery preferred for acute severe ischemia (IIb) requiring immediate revascularization.

What is the Inari ClotTriever for DVT? Inari ClotTriever: mechanical thrombectomy system for DVT (deep vein thrombosis); self-expanding nitinol tube with loops core and collection bag; captures and removes thrombus without thrombolytics; single-session procedure typically; advantages: eliminates thrombolytic bleeding risk; potential complete thrombus removal; preserves venous valves reducing post-thrombotic syndrome; DEFIANCE clinical trial results 2023: superior to CDT for thrombus clearance with lower complication rate; growing adoption for iliofemoral DVT; available in multiple sizes for calf to iliac veins; combined with FlowTriever (PE) creating Inari Medical comprehensive venous portfolio.

#PeripheralIntervention #MechanicalThrombectomy #AcuteLimbIschemia #InariMedical #ClotTriever #DVTthrombectomy